Jules Mbuyamba

Dr. Jules Mbuyamba

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in The Lancet Global Health
Verified
Journal Article
Open access
FMFlorian Marks
Florian Marks
JIJustin Im
Justin Im
SPSe Eun Park
Se Eun Park
GPGi Deok Pak
Gi Deok Pak
HJHyon Jin Jeon
Hyon Jin Jeon
RRRaphaël Rakotozandrindrainy
Raphaël Rakotozandrindrainy
Typhoid Fever remains a major cause of morbidity and mortality in low-income settings. The Severe Typhoid in Africa programme was designed to address regional gaps in typhoid burden data and identify populations eligible for interventions using novel typhoid conjugate vaccines. A hybrid design, hospital-based prospective surveillance with population-based health-care utilisation surveys, was implemented in six countries in sub-Saharan Africa. Patients presenting with fever (≥37·5°C axillary or ≥38·0°C tympanic) or reporting fever for three consecutive days within the previous 7 days were invited to participate. Typhoid fever was ascertained by culture of blood collected upon enrolment. Disease incidence at the population level was estimated using a Bayesian mixture model. 27 866 (33·8%) of 82 491 participants who met inclusion criteria were recruited. Blood cultures were performed for 27 544 (98·8%) of enrolled participants. Clinically significant organisms were detected in 2136 (7·7%) of these cultures, and 346 (16·2%) Salmonella enterica serovar Typhi were isolated. The overall adjusted incidence per 100 000 person-years of observation was highest in Kavuaya and Nkandu 1, Democratic Republic of the Congo (315, 95% credible interval 254-390). Overall, 46 (16·4%) of 280 tested isolates showed ciprofloxacin non-susceptibility. High disease incidence (ie, >100 per 100 000 person-years of observation) recorded in four countries, the prevalence of typhoid hospitalisations and complicated disease, and the threat of resistant typhoid strains strengthen the need for rapid dispatch and implementation of effective typhoid conjugate vaccines along with measures designed to improve clean water, sanitation, and hygiene practices. The Bill & Melinda Gates Foundation.

24 November 2023 in Frontiers in Microbiology
Verified
Journal Article
Open access
LMLisette Mbuyi-Kalonji
Lisette Mbuyi-Kalonji
LHLiselotte Hardy
Liselotte Hardy
Jules MbuyambaJules Mbuyamba
Jules Mbuyamba
MPMarie-France Phoba
Marie-France Phoba
GNGaëlle Nkoji
Gaëlle Nkoji
OLOctavie Lunguya
Octavie Lunguya
Invasive non-typhoidal Salmonella (iNTS) (serotypes Typhimurium and Enteritidis) are major causes of bloodstream infections in sub-Saharan Africa, but their reservoir is unknown. Aiming to demonstrate human carriers as a reservoir, we assessed an iNTS disease endemic rural community (Kikonka health area, Democratic Republic of the Congo) for intestinal carriage of iNTS. After a census, healthy subjects from randomly selected households provided three successive stool samples for Salmonella culture. We next compared the stool isolates for genetic relatedness with time and health area-matched blood culture isolates obtained from hospitalized patients by multiple locus variable-number tandem repeat analysis (MLVA) and performed whole genome sequencing (WGS) on a subset of stool and blood isolates. Among 2,354 eligible subjects, 2,234 (94.9%) consented and provided at least one stool sample, and 2,219 (94.3%) provided three stool samples. The cumulative proportion of Salmonella carriers after 3 days was 4.4% (n = 98). S. Typhimurium and Enteritidis were found in 26 and 3 carriers, respectively, representing 1.3% (29 out of 2,234) of participants living in 6.0% (26 out of 482) of households. MLVA types of all 26 S. Typhimurium stool isolates matched with the corresponding MLVA types of blood isolates. The MLVA type of one out of three Enteritidis stool isolates matched the single MLVA type of the five Enteritidis blood isolates. WGS analysis of S. Typhimurium (n = 20) and S. Enteritidis (n = 4) isolates revealed Typhimurium multilocus sequence type (ST)313 Lineage 2 and Enteritidis ST11 Central/Eastern African and Outlier clades and confirmed the MLVA clustering. More than three-quarters of Typhimurium isolates showed combined multidrug resistance, ceftriaxone resistance, and fluoroquinolone non-susceptibility. In conclusion, the present study demonstrated iNTS carriage among healthy community members, with stool isolates that were genetically similar to blood culture isolates obtained in patients from the same community. These findings contribute to the evidence of a human reservoir of iNTS.

27 January 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
BTBieke Tack
Bieke Tack
DVDaniel Vita
Daniel Vita
Jules MbuyambaJules Mbuyamba
Jules Mbuyamba
ENEmmanuel Ntangu
Emmanuel Ntangu
HVHornela Vuvu
Hornela Vuvu
BCBen Van Calster
Ben Van Calster
Non-typhoidal Salmonella (NTS) frequently cause bloodstream infection in children under-five in sub-Saharan Africa, particularly in malaria-endemic areas. Due to increasing drug resistance, NTS are often not covered by standard-of-care empirical antibiotics for severe febrile illness. We developed a clinical prediction model to orient the choice of empirical antibiotics (standard-of-care versus alternative antibiotics) for children admitted to hospital in settings with high proportions of drug-resistant NTS. Data were collected during a prospective cohort study in children (> 28 days—< 5 years) admitted with severe febrile illness to Kisantu district hospital, DR Congo. The outcome variable was blood culture confirmed NTS bloodstream infection; the comparison group were children without NTS bloodstream infection. Predictors were selected a priori based on systematic literature review. The prediction model was developed with multivariable logistic regression; a simplified scoring system was derived. Internal validation to estimate optimism-corrected performance was performed using bootstrapping and net benefits were calculated to evaluate clinical usefulness. NTS bloodstream infection was diagnosed in 12.7% (295/2327) of enrolled children. The area under the curve was 0.79 (95%CI: 0.76–0.82) for the prediction model, and 0.78 (0.85–0.80) for the scoring system. The estimated calibration slopes were 0.95 (model) and 0.91 (scoring system). At a decision threshold of 20% NTS risk, the prediction model and scoring system had 57% and 53% sensitivity, and 85% specificity. The net benefit for decisions thresholds < 30% ranged from 2.4 to 3.9 per 100 children. The model predicts NTS bloodstream infection and can support the choice of empiric antibiotics to include coverage of drug-resistant NTS, in particular for decision thresholds < 30%. External validation studies are needed to investigate generalizability. DeNTS study, clinicaltrials.gov: NCT04473768 (registration 16/07/2020) and TreNTS study, clinicaltrials.gov: NCT04850677 (registration 20/04/2021).

20 December 2025 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
BTBieke Tack
Bieke Tack
DVDaniel Vita
Daniel Vita
Jules MbuyambaJules Mbuyamba
Jules Mbuyamba
JNJosé Nketo
José Nketo
ENEmmanuel Ntangu
Emmanuel Ntangu
OLOctavie Lunguya
Octavie Lunguya
In sub-Saharan African children aged under 5 years, nontyphoidal Salmonella (NTS) frequently cause fatal bloodstream infections. Antimicrobial resistance and absence of antibiotic treatment efficacy data challenge effective treatment. In this prospective observational study, we provide treatment efficacy data of susceptibility-matched antibiotic regimens from the treatment of NTS bloodstream infections in children in Kisantu district hospital (Democratic Republic of Congo). Children (>28 days to <5 years) admitted with severe febrile illness were enrolled after blood culture sampling. Clinical and microbiological data of children with NTS bloodstream infection were collected in-hospital and at 1-month after discharge. NTS bloodstream infection was diagnosed in 12.7% (239/1867) of enrolled children. Extensive drug-resistance (concurrent ampicillin, cotrimoxazole, chloramphenicol, third-generation cephalosporin and fluoroquinolone nonsusceptibility) occurred in 60% (144/236), i.e. 69% (71/103) in O5-antigen positive Typhimurium, 85% (72/85) in O5-antigen negative Typhimurium but only 2% (1/48) in Enteritidis serovars. Only 64% (146/228) of children received susceptibility-matched antibiotics and overall in-hospital case fatality was 25.1% (60/239). Compared with susceptibility-mismatched antibiotic treatment, susceptibility-matched third-generation cephalosporin treatment on hospital day 0-1 had better 14-day in-hospital survival (hazard ratio at death [HRdeath]: 0.37 [0.16-0.88]). Similarly, susceptibility-matched third-generation cephalosporin, ciprofloxacin or azithromycin treatment on hospital day 2-6 had better 28-day in-hospital survival (HRdeath: 0.21 [0.06-0.68], 0.15 [0.02-1.10] and 0.26 [0.08-0.84], respectively). After ≥5 days of susceptibility-matched antibiotics, NTS persisted in control blood cultures in 15% (13/88). NTS bloodstream infections were often extensively drug resistant, leading to susceptibility-mismatched antibiotic treatment. When NTS were susceptible, third-generation cephalosporin, ciprofloxacin and azithromycin treatment appeared to be effective.

6 March 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
Jules MbuyambaJules Mbuyamba
Jules Mbuyamba
GTGAELLE NKOJI TUNDA
GAELLE NKOJI TUNDA
DVDaniel Vita
Daniel Vita
LNLaurence NGARA
Laurence NGARA
EBEdmonde Bonebe
Edmonde Bonebe
OLOctavie Lunguya
Octavie Lunguya
Background: Antimicrobial resistance (AMR), particularly due to extended-spectrum beta-lactamases (ESBL), is a growing threat to public health in sub-Saharan Africa. This study investigates the prevalence, epidemiological characteristics, resistance patterns and resistance dynamic over time of ESBL-producing non-typhoidal Salmonella (NTS) bacteremia in Kisantu, Democratic Republic of Congo (DRC), from 2019 to 2022. Methods: A retrospective observational study used routine bloodstream infection data from the AMR network at Saint Luc Hospital in Kisantu. Blood cultures from suspected bacteremia cases were processed using standard microbiological techniques. Bacterial identification relied on biochemical reactions. Antibiotic susceptibility testing and ESBL-producing NTS detection were performed by disk diffusion following Clinical and Laboratory Standards Institute guidelines. Associations between ESBL production and patient characteristics (age, sex) were assessed using Pearson’s Chi-square test, and annual temporal trends in ESBL-producing NTS from 2019 to 2022 were analyzed by logistic regression using 2019 as the reference year. Results: Of the 19,430 blood cultures, 1681 NTS isolates were identified, and 1568 of these were screened for ESBL. ESBL prevalence was significantly associated with age (p = 0.007), peaking in children under 2 years, but not with sex (p = 0.570). Compared with 2019, the likelihood of isolating ESBL-producing NTS increased markedly through 2022, with adjusted probabilities rising from 58% to 87%, reflecting a strong upward temporal trend. High levels of extensively drug-resistant (94.1%) were observed. No carbapenem resistance was detected. Conclusions: ESBL-producing NTS bacteremia is rising in Kisantu, DRC, mainly affecting children under 2 years. Rising resistance to key antibiotics limits treatment options and highlights the need for strengthened AMR surveillance, optimized antibiotic use, and vaccination strategies.

19 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Jules MbuyambaJules Mbuyamba
Jules Mbuyamba
GTGAELLE NKOJI TUNDA
GAELLE NKOJI TUNDA
DVDaniel Vita
Daniel Vita
LNLaurence NGARA
Laurence NGARA
EBEdmonde Bonebe
Edmonde Bonebe
OLOctavie Lunguya
Octavie Lunguya
Background: Antimicrobial resistance (AMR), particularly due to extended-spectrum beta-lactamases (ESBL), is a growing threat in sub-Saharan Africa. This study investigates the prevalence, epidemiological characteristics, resistance patterns and over time resistance dynamics of ESBL-producing non-typhoidal Salmonella (NTS) bacteremia in Kisantu, Democratic Republic of Congo (DRC), from 2019 to 2022. Methods: A retrospective observational study used routine bloodstream infection data from the AMR network at Saint Luc Hospital in Kisantu. Blood cultures from suspected bacteremia cases were processed using standard microbiological techniques. Bacterial identification relied on biochemical reactions. Antibiotic susceptibility testing and ESBL-NTS detection were performed by disk diffusion following Clinical and Laboratory Standards Institute guidelines. Quarterly temporal trends in ESBL-positive NTS were evaluated using logistic regression. Results: Of 19,430 blood cultures, 1,681 NTS isolates were identified, 1,568 were screened for ESBL. ESBL production was detected in 1,184 isolates (75.5%), mostly from children under 5 years (1,098/1,184; 92.7%), including nearly 72% under 24 months. ESBL prevalence increased significantly over time (β = 0.139, OR = 1.15, 95% CI: 1.11–1.19, p < 0.001), rising from 14.3% in Q (Quarter) 1 2019 to 95.3% in Q3 2022. High levels of extensively drug-resistant (94.1%) and pan-drug-resistant (6.3%) isolates were observed. No carbapenem resistance was detected, and azithromycin resistance remained low (6.4%). Conclusion: ESBL-producing NTS bacteremia is rising in Kisantu, RDC, manly affecting children under 5 years. Rising resistance to key antibiotics limits treatment options and highlights the need for strengthened AMR surveillance, optimized antibiotic use, and vaccination strategies.